Department of General Surgery, Huashan Hospital of Fudan University, Shanghai, China.
Department of Urology, Huashan Hospital of Fudan University, Shanghai, China.
Int J Obes (Lond). 2024 Apr;48(4):469-476. doi: 10.1038/s41366-023-01435-w. Epub 2023 Dec 11.
Obesity and non-alcoholic fatty liver disease (NAFLD) are major health concerns. The circadian rhythm is an autonomous and intrinsic timekeeping system closely associated with energy metabolism and obesity. Thus, this study explored the role of brain and muscle aryl hydrocarbon receptor nuclear translocator-like1 (BMAL1), a circadian clock regulator, in the development of obesity and NAFLD.
We generated BMAL1 knockout (BMAL1 KO) mice to imitate circadian rhythm disruption. The study comprised three groups from the same litter: BMAL1 KO mice fed a high-fat diet (to establish obesity and NAFLD phenotypes), wild-type mice fed normal chow, and wild-type mice fed a high-fat diet. The metabolic and NAFLD phenotypes were assessed via physiological measurements and histological examinations. Quantitative polymerase chain reaction and western blotting were used to identify and validate changes in the signaling pathways responsible for the altered NAFLD phenotypes in the wild-type and BMAL1 KO mice.
BMAL1 depletion protected against obesity and metabolic disorders induced by a high-fat diet. BMAL1 depletion also prevented hepatic steatosis and inhibited cluster of differentiation 36 and peroxisome proliferator-activated receptor gamma (i.e., PPARγ) expression.
BMAL1 plays an important role in the development of obesity and NAFLD and, thus, is a potential therapeutic target for these conditions.
肥胖和非酒精性脂肪性肝病(NAFLD)是主要的健康问题。昼夜节律是与能量代谢和肥胖密切相关的自主和内在的计时系统。因此,本研究探讨了生物钟调节因子脑和肌肉芳香烃受体核转位蛋白样 1(BMAL1)在肥胖和 NAFLD 发展中的作用。
我们生成了 BMAL1 敲除(BMAL1 KO)小鼠来模拟昼夜节律紊乱。这项研究包括来自同一窝的三组:高脂肪饮食喂养的 BMAL1 KO 小鼠(建立肥胖和 NAFLD 表型)、正常饮食喂养的野生型小鼠和高脂肪饮食喂养的野生型小鼠。通过生理测量和组织学检查评估代谢和 NAFLD 表型。定量聚合酶链反应和蛋白质印迹用于鉴定和验证野生型和 BMAL1 KO 小鼠中负责改变的 NAFLD 表型的信号通路的变化。
BMAL1 耗竭可预防高脂肪饮食引起的肥胖和代谢紊乱。BMAL1 耗竭还可预防肝脂肪变性,并抑制分化群 36 和过氧化物酶体增殖物激活受体γ(即 PPARγ)的表达。
BMAL1 在肥胖和 NAFLD 的发展中起重要作用,因此是这些疾病的潜在治疗靶点。